Objective: The aim of this study was to assess the antibody response to combined passive-active immunization versus active immunization against hepatitis B in 71 patients with acute leukemia with negative hepatitis B virus serology at presentation. (Turk J Hematol 2010; 27: 156-61) Key words: Acute leukemia, hepatitis B vaccine, hepatitis B immunoglobin Received: May 27, 2009 Accepted: April 30, 2010 Özet Amaç: Bu çalışmada, prezantasyonda negatif Hepatit B virüsü serolojisine sahip akut lösemili 71 hastada Hepatit B virüsüne karşı aktif aşılama karşısında birleşik pasif aktif aşılamaya yönelik antikor yanıtının değerlendirilmesi amaçlanmıştır.
Introduction
Hepatitis B is one of the most important causes of acute and chronic hepatitis. Children with malignant disease are at an especially high risk for developing hepatitis B virus (HBV) infection from immunosuppression secondary to chemotherapy, radiotherapy and multiple blood transfusions. Most of the children infected with HBV develop chronic hepatitis. This plays an adverse prognostic role in terms of their disease-free survival because of delays in chemotherapy. The increasing potential for the cure of childhood malignant diseases emphasizes the need for a method of reducing hepatitis and its sequelae in these children.
Hepatitis B virus infection is prevalent in India. Among blood donors, pregnant women and the general population whose carrier frequency is 2%-4% and hepatitis B surfact antibody (anti-HBs) positivity is around 18%-20% [1] . A high proportions of children treated for malignant disorders demonstrate seroconversion for HBV infection markers [2] .
The high prevalence of HBV infection and relative failure of active immunization in patients with leukemia on therapy have prompted a search for alternative forms of prophylaxis [3] . Various studies have observed a decreased rate of transmission of the infection with passive immunization [4] . Thus, for protection against HBV infection, both active and passive immunization have been tried [5, 6] .
Since there are very few studies in this context, this study was undertaken to determine the efficacy of immunization (both active and passive) against HBV infection in acute leukemia patients.
Materials and Methods
The aims and objectives of this study were to determine the incidence of hepatitis B surface antigen (HBsAg) positivity before treatment, the efficacy of hepatitis B vaccine along with HBIG (hepatitis B immunoglobulin) in patients with acute leukemia, the anti-HBs titer level in the course of treatment and up to six months, and the HBsAg positivity rate in the course of treatment up to six months. A total of 114 patients with acute leukemia were tested for HBsAg and anti-HBs titer before starting treatment. Of the 114 patients, 3 were positive for HBsAg and 111 patients were negative for HBsAg. Out of 111 patients, 40 had anti-HBs titer ≥10 IU/L and 71 patients had anti-HBs titer <10 IU/L. Thus, 71 patients were included in this study. This project was approved by the All India Institute of Medical Sciences (AIIMS) Ethics Committee. It is a prospective comparative trial including patients with acute leukemia with HBsAg, anti-HBs negativity before treatment and with anti-HBs titer <10 IU/L. Those patients already immunized and with protective anti-HBs titer ≥10 IU/L were excluded from the study. Those who already completed immunization against hepatitis B and with anti-HBs titer <10 IU/L were also included in this study. Immunization was started from induction. The first group (n=28) received hepatitis B vaccine (Engerix BGlaxoSmithKline Biologicals, double dose, i.e. ≤11 years 20 mcg and >11 years 40 mcg) at 0, 1, 2, and 6 months and HBIG (Hepabig-VHB Life Sciences Limited, Mumbai, India at a dose of 40 IU/kg maximum of 800 IU) at 0 and 1 month concurrently with HBsAg and anti-HBs titer were determined one month after the 1st, 2nd, 3rd and 4th doses of vaccine. In those patients who were given Engerix B and HBIG and became HBsAg positive after starting treatment, subsequent doses of Engerix B and HBIG were not given. Anti-hepatitis C virus (HCV) total and human immunodeficiency virus (HIV) antibody were also tested before starting treatment and one month after the 4th dose of vaccine. HbsAg was tested using Hepanostika ® HBsAg Ultra (bioMerieux bv Boseind 15, 5281RM Boxtel, The Netherlands). Anti-HBs was tested using VIDAS ® (bioMérieux ® sa, France).
Fisher's exact test and chi-square test were used to compare proportions between the groups. McNemar test was used to compare proportions within the group. Wilcoxon rank-sum (MannWhitney U) test was used to compare the medians. Two-sample t test was used to compare the median between the groups in equal variances. The statistical tests were performed by using STATA 9.0 and SPSS software version 11.5 for Windows ® .
Results
Of these 114 patients, 3 (3%) were positive for HBsAg and 111 patients (97%) were negative for HBsAg. Out of 111 patients, 40 (36%) had anti-HBs titer ≥10 IU/L and 71 (64%) had anti-HBs titer <10 IU/L. Of those patients with anti-HBs titer ≥10 IU/L, 7 (18%) patients had past history of jaundice, 13 (33%) had history of previous vaccination and 20 (49%) had no history of jaundice or previous vaccination. A significant statistical difference (p=0.04) was found between pediatric and adult patients in anti-HBs titer ≥10 IU/L and anti-HBs titer <10 IU/L groups. The majority of pediatric patients had antiHBs titer ≥10 IU/L compared to adults before starting chemotherapy.
The median age was 22 years (range, 1-52); 49 (69.01%) were male and 22 (30.99%) were female ( Table 1 ). The total number of pediatric (≤18 yrs) patients was 31 (43.66%) and of adult (>18 yrs) patients was 40 (56.34%). The total number of acute lymphoblastic leukemia (ALL) patients was 38 (53.52%) and of acute myeloid leukemia (AML) patients was 33 (46.48%). Nine patients (12.67%) died due to their disease and chemotherapy complications before the 2 nd dose of vaccine; thus, 62 patients received a 2 nd vaccine dose. Three patients died before receiving their 3 rd dose of vaccine; thus, 59 patients received a 3 rd vaccine dose. One patient died before receiving their 4 th dose of vaccine; thus, 58 patients received a 4 th vaccine dose.
In cine-only group, after the 4th dose, anti-HBs titer ≥10 IU/L was achieved in 34.29% of patients, which was a very small proportion compared to the HBIG group. In both groups, a subgroup analysis was done between the ALL vs AML groups and pediatric vs adult groups. No significant differences were found between the ALL vs AML groups or between the pediatric vs adult groups. In the pediatric age group, 72.72%, 58.33%, 47.61% and 41.37% patients developed anti-HBs titer ≥10 IU/L after the 1 st , 2 nd , 3 rd and 4 th doses of vaccine, respectively, whereas in the adult age group, 27.28%, 41.67%, 52.38% and 58.63% patients developed anti-HBs titer ≥10 IU/L after the 1 st , 2 nd , 3 rd and 4 th doses of vaccine, respectively. This showed that pediatric patients lost their anti-HBs titer gradually from the 1st to the 4 th dose of vaccine. On the other hand, an increasing number of adult patients gained anti-HBs titer ≥10 IU/L gradually from the 1 st to the 4 th dose of vaccine. Statistical differences in antiHBs titer ≥10 IU/L were seen between the two age groups after the 1 st (p=0.002) and 2 nd (p=0.01) dose of vaccine, but not after the 3 rd (p=0.40) and 4 th (p=1.00) dose of vaccine. Thus, more pediatric patients developed anti-HBs titer ≥10 IU/L after the 1 st and 2 nd doses of vaccine compared to adult patients. Though more adult patients gained protective anti-HBs titer gradually from the 3 rd to 4 th doses of vaccine, when compared to the pediatric age group, the difference was statistically insignificant.
In the ALL group, 81.81%, 70.84%, 47.62% and 55.17% patients developed anti-HBs titer ≥10 IU/L after the 1 st , 2 nd , 3 rd and 4 th doses of vaccine, respectively, whereas in the AML group, 18.19%, 29.16%, 52.38% and 44.83% patients developed antiHBs titer ≥10 IU/L after the 1 st dose, 2 nd , 3 rd and 4 th doses of vaccine, respectively. After the 1 st dose of vaccine, a statistical difference in anti-HBs titer ≥10 IU/L was seen between the ALL and AML groups. No statistically significant differences were found after administration of the other doses (p values: 0.06 after 2 nd dose, 0.28 after 3 rd dose and 1.00 after 4 th dose). A significant number of ALL patients developed protective antibody titer after the 1st vaccine dose compared to AML patients; thereafter, both groups behaved similarly.
One month after the 4 th dose of vaccine, out of 58 patients, 5 patients (8.6%) were found HBsAgpositive. Among the HBsAg-positive patients, 1 (4.34%) was in the HBIG group and the remaining 4 (11.42%) were in the vaccine-only group. Of the HBsAg-positive patients, 3 had ALL and 2 had AML. No significant difference (p=0.63) in HBsAg positivity was found between the vaccine groups. After 210 days of follow up, none of the patients was found to be positive for anti-HCV or HIV antibody.
Discussion
A study from India showed that 47.8% of ALL patients were positive for HBsAg after therapy. In order to reduce the impact of HBV infection, schedules for active immunization, double doses of active immunization and both active and passive immunization against this infection have been investigated.
The HBsAg positivity rate (3%) in our study is quite similar to that of other studies performed in the general population in India. But the anti-HBs positivity rate in our study is quite high (40%) compared to other studies (18-20%) performed from India. This is probably due to the increased awareness of hepatitis B vaccination in the general popu- Goyal et al. [3] showed that after administration of double-dose vaccine during induction, consolidation and maintenance (0-1-2-12 months) chemotherapy, 19.7% patients developed anti-HBs titers and anti-HBs titer ≥10 IU/L was achieved in only 10.5% of patients. They detected HBsAg in 48.79% of their patients during the course of treatment. Another study from India by Somjee et al. [7] showed that at the end of six doses of vaccine (0-1-2-3-4-12), 29.75% of patients developed anti-HBs titers, and of them, only 18.9% had anti-HBs titer ≥10 IU/L. In the course of treatment, 43% of patients developed HBsAg positivity. A similar dose schedule as in our study (0-1-2-6) was tried in adult patients with acute leukemia (ALL & AML) by Gurina et al. [8] . In 30 patients, the rate of antibody positivity was 50% after the 4th dose of vaccine and 6.7% became infected with HBV over the three-year follow-up. A more intensive vaccination schedule (0-1-2-6-12) was used by Yetgin et al. [9] in 82 patients with childhood ALL. They found that the rate of antibody positivity was 35.4% after the 5 th dose of vaccine, and 4.8% became infected with HBV after the end of vaccination. Our results are quite similar with the Yetgin et al. trial. An exact comparison with other studies is not possible because different vaccination schedules were used. In our study, more patients (34.29%) developed protective antibody titer after receiving their 4 th dose of vaccine compared with other trials done by Goyal et al. [3] and Somjee et al. [7] . This is possibly due to the more severe immunosuppressive chemotherapy schedule used in their study. In our study, after a seven-month follow-up period, a small number (11.42%) of patients developed HBsAg positivity compared with other trials done by Goyal et al. and Somjee et al. This is due to improved infection control measures, safer blood supply in our hospital and the short duration of follow-up in our study. In spite of active immunization with recombinant DNA vaccine, some patients became infected with HBV infection. Thus, active immunization with recombinant DNA vaccine has a minimal role in these immunosuppressed patients while they are on aggressive therapy.
A total of 28 patients received both vaccine and HBIG. Passively transferred immunity generated high titers of antibodies in these patients in the first 3 months. However, once these were eliminated over a period of another 3 months, active immunization was unable to confer sustained protection at 7 months. Therefore, it should be stressed that passive prophylaxis alone needs to be administered during the entire course of aggressive chemotherapy. Kavakli et al. [4] studied 22 patients with leukemia who received HBIG (800 IU once per month for 3 doses), together with vaccine at a different intramuscular site. HBV infection was not observed in any of the patients at the 4 th and 12 th months of serological follow-up. At the end of the first year, the antibody response reached 85%. In another study by Meral et al. [6] , passive immunization with immunoglobulin (monthly for four doses) was given at the time of aggressive chemotherapy, and subsequently these patients were actively immunized with vaccine (40 mcg, 1-2-12 months) from the third month of maintenance therapy. Their rate of antiHBs positivity was 90.3% at the end of the four doses, and at the end of the three-year follow-up, only 5 patients (16%) lost the protective antibody titers. In another Indian study by Somjee et al. [5] , five doses of hepatitis B vaccine (ENGERIXSmithKline Beecham) along with HBIG (HEPABIG-VHB Pharmaceuticals) were given in 31 ALL patients. Their rates of anti-HBs positivity were 89.6% at the end of 6 months, and at the end of 9 months, only 8 (42%) patients had lost the protective antibody titer. The rate of HBV infection was 27% at the end of 9 months. In our study, 73.91% of patients had developed anti-HBs titer ≥10 IU/L 1 month after the 4th dose of vaccine. This is a slightly inferior response compared to results of the Kavakli et al. [4] , Meral et al. [6] and Somjee et al. [7] trials. The inferior response is possibly due to lesser doses of HBIG used in our trial (i.e. 2 doses of HBIG in our trial, 3 doses in Kavakli et al. trial, 4 doses in Meral et al. trial and 5 doses in Somjee et al. trial). Thus, a comparison of our study and other studies clearly shows that more doses of HBIG are required to achieve the maximum protective anti-HBs titers. Apart from that, HBIG may protect patients during the intensive chemotherapy period, but there must be sufficient antibody level during the entire period to decrease the rate of HBV infection in these patients. HBIG
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In normal individuals, the rate of seroconversion following hepatitis B vaccine is almost 96%, and protective antibody levels can be achieved in 93% [3] . In the present study, despite the use of a double dose of vaccine and a more intensified vaccination program, seroconversion could be achieved in only 34.29% and 73.91% of the patients in the vaccineonly and vaccine-HBIG groups, respectively. This is because immunosuppression in leukemic patients resulting from the disease as well as the use of steroids lead to diminished response to initial or booster vaccination. Therefore, passive immunization with hyperimmunoglobulin followed by active immunization starting during maintenance therapy or after cessation of intensive chemotherapy may be a better alternative to achieve permanent protective antibody titers.
In the HBIG group, subgroup analysis was done between the ALL vs AML and pediatric vs adult groups. No statistically significant differences were found between the ALL vs AML groups or between the pediatric vs adult groups. Thus, differences in age and disease were not responsible for development of protective antibody titer. HBsAg positivity rate was similar between the two vaccine groups in the short follow-up period (7 months). The outcome of long-term follow-up might be different in terms of HBsAg positivity. Thus, long-term followup will be required to determine the efficacy of vaccination and the HBsAg positivity rate.
In conclusion, HBIG may protect patients during the intensive chemotherapy period, but there must be sufficient antibody level during the entire period to decrease the rate of HBV infection in these patients. To increase the level of protective antibody titers (≥10 IU/L), both active and passive immunization are required. A large prospective multicenter randomized controlled trial is needed to address this issue.
